Clinical trial 470 x 80 (new) 

Neurosearch's license partner Abbott initiates clinical Phase I

30 July - Neurosearch's development and license partner Abbott has enrolled and dosed the first patients in a clinical Phase I study with the drug candidate ABT-560, which has treatment potential within a variety of CNS disorders. Read more

Phase III study with insulin sensitizer performed by Rheoscience A/S

1 August - Rheoscience A/S and Dr. Reddy's Laboratories has announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated receptor) gamma agonist. Read more 

Genzyme announces second Pivotal Mozobil trial meets primary Endpoint

2 August - Genzymes second Phase III trial of Mozobil (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similiar to those reported two weeks ago in non-Hodgkin's lymphoma. Read more